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 Abstract 
The IFN-inducible human IFI16 gene is highly expressed in endothelial cells as well as epithelial 
and hematopoietic tissues. Previous gene array analysis of human umbilical vein endothelial cells 
overexpressing IFI16 has revealed an increased expression of genes involved in inflammation and 
apoptosis. In this study, protein array analysis of the IFI16 secretome showed an increased 
production of chemokines, cytokines and adhesion molecules responsible for leukocyte chemotaxis. 
Functional analysis of the promoter for CCL20, the chemokine responsible for leukocyte 
recruitment in the early steps of inflammation, by site-specific mutation demonstrated that NF-κB is 
the main mediator of CCL20 induction at the transcriptional level. Finally, both Langerhans DC and 
B-lymphocyte migration triggered by supernatants from IFI16-overexpressing endothelial cells was 
partially inhibited by Ab inactivating CCL4, CCL5 and CCL20 chemokines. Altogether, these 
results demonstrate that the IFI16 gene, through its secretome, regulates proinflammatory activity of 
endothelial cells, thus corroborating its role in the early steps of inflammation. 
  
Introduction 
The IFI16 gene, a member of the HIN200 family, encodes a nuclear phosphoprotein 1–3 believed to 
belong to the DNA repair system and is triggered by various stimuli including IFN (IFN-α/β and -
γ), oxidative stress, cell density and some proinflammatory cytokines, such as TNF-α 4, 5. In 
addition to partially conserved repeat motifs of 200 amino acids, designated A, B and C, the IFI16 
protein contains a DAPIN/PYRIN domain within its N-terminus 6, 7. This domain was identified as 
a putative protein–protein interaction domain at the N-terminus of several other proteins believed to 
function in inflammatory signalling pathways. Consistent with these observations, prominent in 
vivo IFI16 expression has been demonstrated in lymphocytes, monocytes, stratified squamous 
epithelia and endothelial cells (EC) isolated from both blood and lymph vessels 8, 9, suggesting a 
role for IFI16 in the modulation of inflammation and the immune response. We have previously 
shown that IFI16 overexpression in EC triggered at the transcriptional level the expression of both 
adhesion molecules (such as ICAM-1) and chemokines (such as CCL2 and CCL20) 9. The 
treatment of cells with short hairpin RNA, targeting IFI16 significantly inhibited ICAM-1 induction 
by IFN-γ demonstrating that IFI16 is required for proinflammatory gene stimulation by this 
cytokine. Moreover, functional analysis of the ICAM-1 promoter demonstrated that NF-κB, one of 
the main transcription factors activated during inflammation, is the main mediator of IFI16-driven 
ICAM-1 induction by IFN-γ. Additionally, anti-IFI16 autoAb are present at much greater levels in 
patients with autoimmune diseases, such as cutaneous systemic sclerosis, systemic lupus 
erythematosus and Sjogren's syndrome, compared with normal controls 10, 11. 
A common complication in autoimmune connective tissue diseases is vascular involvement 12. A 
reduction in the number of capillaries has been observed associated with endothelial swelling, 
basement membrane thickening and hyperplasia of the intima with infiltration of inflammatory cells 
into the skin 12. Considering this scenario in mind, one can hypothesize that IFI16 is involved in 
the early steps of inflammation resulting in EC activation – a necessary condition for the 
development of autoimmune diseases. 
The aim of this study was to verify whether inflammatory molecule induction by IFI16 is confined 
to adhesion molecules, such as ICAM-1, or if it can also be extended to proinflammatory 
chemokines that are responsible for inflammatory cell recruitment, such as CCL4, CCL5 and 
CCL20, thereby reinforcing the physiological relevance of IFI16 in the early steps of inflammation. 
 
 
Results 
We have previously analyzed transcriptomes from EC overexpressing IFI16 and found that IFI16 
upregulates a complex array of cellular genes encoding inflammatory molecules responsible for 
leukocyte recruitment 9. Moreover, we showed that IFI16 triggers the expression of EC ICAM-1 9 
– an adhesion molecule involved in the enrolment of cells at the site of inflammation during the first 
steps of inflammation 13. In this study, in order to determine whether IFI16 also induces the 
secretion of chemokines and cytokines, we first analyzed the IFI16 secretome for 174 common 
chemokines, cytokines and growth factors using RayBio human cytokine array G Series 2000 Ab 
arrays. A comparison of the supernatants from cultured human umbilical vein EC (HUVEC)-
overexpressing IFI16 with those from control HUVEC cultures infected with the LacZ transgene 
indicated 12 significantly induced molecules (Table 1). The most abundant inflammatory factors in 
the IFI16 secretome included the chemokines/cytokines CCL3, CCL4, CCL5, CCL20 and IL-1β, 
along with the growth regulatory factor amphiregulin (AREG). Consistent with the previous results 
showing induction of ICAM-1 at the transcriptional level, IFI16 overexpression also induced the 
expression of the soluble form of ICAM-1. Validation of the protein array analysis for some of the 
proteins identified from the secretome analysis was performed using real-time PCR (RT-PCR). 
Primer sequences were designed using the program qPrimerDepot 
(http://primerdepot.nci.nih.gov.offcampus.dam.unito.it/) directed at both the 3′ and 5′ ends of the 
gene sequence. The gene-specific primers used in this study are listed in Table 2. RT-PCR analysis 
largely confirmed secretome analysis. As shown in Fig. 1, IFI16 modulates the expression of 
endothelial genes, such as ICAM-1, implicated in the early steps of inflammation. Indeed, CCL3, 
CCL4, CCL5, CCL20 and IL-1β were significantly upregulated (33.5-fold, 21-fold, 9.5-fold, 18.5-
fold and 28.5-fold, respectively), indicating that the RT-PCR results were generally consistent with 
the expression patterns observed in the secretome analysis (Table 1). 
 
 
 
 
 
 
Table 1. Analysis of IFI16 secretome in EC 
 
Factor values (in arbitrary units) were determined by RayBiotech protein array analysis. 
Averages7SD are shown for AdVLacZ- and AdVIFI16-infected intensity values. 
 
 
Figure 1. Validation of IFI16 secretome analysis in EC at the mRNA level. Total cellular RNA was 
extracted from HUVEC infected with AdVIFI16 or AdVLacZ at an MOI of 300 for 24 h and 
reverse transcribed into cDNA; the expression levels of the indicated genes were assessed by RT-
PCR. Data show mean±SEM from three independent experiments. *p<0.05, **p<0.01, ***p<0.001; 
unpaired Student's t-test. 
 
Table 2. List of primers for secretome validation 
 
As IFI16 increases the expression of genes encoding inflammatory chemokines, to confirm these 
inductions at the protein level, representative chemokines were also quantified by ELISA in 
supernatants from both LacZ and IFI16 HUVEC supernatants 60 h postinfection. As shown in Fig. 
2, the CCL4 protein levels are 28-fold higher in supernatants from IFI16 HUVEC-infected cells 
compared with those in the supernatants from LacZ-infected cells (86±24 versus 3±4 pg/mL, 
mean±SEM), the CCL5 protein levels are fourfold higher (273±39 versus 74±32 pg/mL) and the 
CCL20 protein levels are about threefold higher in supernatants from IFI16 HUVEC-infected cells 
(312±30 versus 102±8 pg/mL). This analysis provides the first glimpse into the complexity of the 
IFI16 secretome and confirms its ability to trigger proinflammatory activity in EC. 
 Figure 2. ELISA analysis of IFI16-induced chemokines. Supernatants from AdVLacZ- and 
AdVIFI16-infected HUVEC (MOI 300) were collected 60 h postinfection and analyzed by ELISA 
(R&D Systems). Data show mean±SEM from three independent experiments. *p<0.05, **p<0.01; 
unpaired Student's t-test. 
 
The IFI16 gene is known to be induced by IFN, however, to confirm the role of IFI16 as the 
mediator of IFN pro-inflammatory activity, we investigated whether the array of inflammatory 
molecules stimulated in HUVEC by treatment with IFN-β overlapped with that observed in IFI16-
infected cells. To do so, EC were treated with IFN-β or left untreated. After 24 h, total RNA were 
extracted, retrotranscribed into cDNA and analyzed by RT-PCR and the arrays of expressed 
proinflammatory genes compared. As shown in Fig. 3, treating HUVEC with IFN-β resulted in the 
upregulation of a series of proinflammatory genes, including ICAM-1, CCL3, CCL4, CCL5, 
CCL20 and IL-1β (6.35-fold, 10.4-fold, 6.1-fold, 58.7-fold, 26.8-fold and 8.71-fold, respectively) 
that were also observed to be upregulated in HUVEC overexpressing IFI16. 
 
Figure 3. IFI16 and secretome induction following IFN-β treatment in EC. Total cellular RNA was 
extracted from HUVEC treated with 1000 U/mL of IFN-β for 24 h or left untreated (NT) and 
reverse transcribed into cDNA. Then the expression levels of the indicated genes were assessed by 
RT-PCR. Data show mean±SEM from three independent experiments. *p<0.05, **p<0.01, 
***p<0.001; unpaired Student's t-test. 
 
To determine whether the increase in expression of inflammatory molecules was a consequence of 
stimulating the encoding genes at the transcriptional level, we analyzed the effects of IFI16 on the 
expression of the transiently transfected luciferase reporter gene driven by the promoters of either 
CCL20 or ICAM-1. HUVEC were transiently transfected with the indicated plasmids and then 
infected with either adenovirus containing the IFI16 gene (AdVIFI16) or AdVLacZ, or otherwise 
left uninfected. Thirty-six hours postinfection, cell extracts were prepared and assayed for luciferase 
activity. As shown in Fig. 4, IFI16 overexpression led to an increase in the expression of the 
luciferase reporter gene driven by either the CCL20 promoter (3.8-fold) or the ICAM-1 promoter 
(11.5-fold) (used as positive control) compared with extracts from AdVLacZ-infected HUVEC. 
 Figure 4. Mutational analysis of putative IFI16-responsive elements in the CCL20 promoter. 
HUVEC were transfected with the indicated constructs and 24 h later infected with either AdVIFI16 
or AdVLacZ at an MOI of 300. After a further 36 h of incubation, protein extracts were prepared 
and assessed for luciferase activity. The p5×NF-κB-luc vector was used to test IFI16 activity on 
NF-κB binding sites. Data show mean±SEM from three independent experiments are shown; data 
are expressed as fold changes in the induction of promoter activity compared with the AdVLacZ-
infected cells. *p<0.05, **p<0.01; unpaired Student's t-test. 
Previous results have demonstrated that NF-κB is the main mediator of IFI16-driven ICAM-1 
induction responsible for leukocyte adhesion to the endothelium 9. To determine whether the 
interaction of IFI16 with NF-κB may also be responsible for the induction of other genes within the 
IFI16 secretome, functional analysis of the CCL20 gene promoter was performed. To do this, 
transient transfection assays were performed using either one of the two human CCL20 promoter-
luciferase constructs: pCCL20 c/EBPmut, containing the full-length human CCL20 promoter 
bearing the mutated c/EBP site; and the pCCL20 NF-κBmut, containing the full-length CCL20 
promoter bearing the mutated NF-κB site 14. As shown in Fig. 4, site-specific mutation of the 
single NF-κB responsive motif almost completely blocked the ability of IFI16 to trigger luciferase 
activity. In contrast, mutation of the single C/EBP site only slightly decreased luciferase activity 
compared with the wild-type CCL20 promoter. 
In order to provide definitive evidence supporting the role of NF-κB as the mediator of CCL20 
promoter activation by IFI16, HUVEC were transfected with the indicator plasmid 5× NF-κB luc 
15, infected thereafter with AdVIFI16 or AdVLacZ and reporter gene activity subsequently 
measured 24 h later. As shown in Fig. 4, overexpression of IFI16 significantly increased NF-κB 
transactivation of the reporter gene although at levels lower than those observed with the 
endogenous CCL20 promoter. Altogether, these results demonstrate that IFI16 interacts with NF-κB 
in order to trigger CCL20 promoter activity, in line with the results obtained from the ICAM-1 
promoter analysis. However, NF-κB does not appear to be the only transactivator stimulated by 
IFI16 in order to trigger CCL20 promoter. 
The ligand–receptor pair CCL20-CCR6 is believed to be responsible for the chemoattraction of 
CD34-derived immature DC, Langerhans DC (L-DC), effector/memory T cells and B cells, and it 
plays a role at skin and mucosal surfaces under homeostatic and inflammatory conditions 16, 17. If 
this is the case, it is important to verify a functional link between the ability of IFI16 to trigger 
CCL4, CCL5 and CCL20 release by HUVEC and DC and B-lymphocyte chemoattraction. Using a 
transwell migration assay, we demonstrate that both L-DC and B cells migrate to a significantly 
greater degree in response to the supernatants from IFI16-infected HUVEC compared with the 
supernatants from LacZ-infected HUVEC (Fig. 5). This migration was significantly reduced by pre-
incubation with the anti-CCL4, anti-CCL5 and anti-CCL20 mAb, but only when added to the 
supernatants from IFI16-infected HUVEC. In contrast, addition of an unrelated mAb of the same 
isotype, used as an internal control, did not influence cell migration (data not shown). These results 
confirm that the secretion of CCL4, CCL5 and CCL20 by IFI16-infected HUVEC is functional and 
important for inducing L-DC and B-cell migration into the mucosa and skin where these cells are 
particularly abundant. Moreover, the only partial anti-CCL4, anti-CCL5 and anti-CCL20 mAb-
induced inhibition of cell migration can be explained by the finding that the IFI16 secretome also 
contains other chemoattractant chemokines (Table 1) that contribute to the modulation of L-DC and 
B-cell migration. 
 Figure 5. The supernatants from IFI16-infected HUVEC induce L-DC and B-cell migration. (A) 
Monocyte-derived L-DC express CD1a, CCR6 and langerin. The thin line shows the negative 
control, the thick line L-DC stained with the indicated mAb. Data are representative of six 
independent experiments with different donors. (B) In vitro-generated L-DC and (C) purified B 
cells were cultured in the presence of AdVLacZ-infected (white columns) and AdVIFI16-infected 
(grey columns) HUVEC supernatants for 2 h in the upper chamber of transwell plates in the 
presence of specific anti-CCL4, anti-CCL5 and anti-CCL20 mAb. Data show mean±SEM of three 
independent experiments. *p<0.05, **p<0.01: for AdVIFI16 versus AdVLacZ; °p<0.05, °°p<0.01, 
°°°p<0.001: for AdVIFI16-treated cells versus AdVIFI16-untreated cells; unpaired Student's t-test. 
 
Discussion 
Chemokines, basic proteins that strongly bind to heparin, can induce leukocyte chemotaxis and 
activation and are intimately involved in various biological processes, including inflammatory 
responses, hematopoietic regulation and neoangiogenesis 18–20. The chemokines CCL4, CCL5 and 
CCL20 have been reported as being capable of attracting memory/activated T cells, whereas 
immature DC and B cells express CCR6 – its specific CC chemokine receptor 20, 21. 
Previous DNA microarray analysis has revealed that IFI16 overexpression in EC triggers the 
expression of proinflammatory adhesion molecules, and functional analysis of the ICAM-1 
promoter by site-specific mutagenesis has demonstrated that NF-κB is the main mediator of IFI16-
driven gene induction 9. However, definitive prove that IFI16 regulates the proinflammatory 
activity of EC at the functional level has been missing. In this study, protein array analysis of the 
IFI16 secretome reveals that IFI16 triggers the expression of both intercellular adhesion molecules 
and chemokines responsible for leukocyte recruitment in vivo. Consistent with these observations, 
significant increases in the protein levels of CCL4, CCL5 and CCL20 were identified by ELISA in 
the supernatants of HUVEC overexpressing IFI16. Moreover, studying CCL20 as a representative 
chemokine, we demonstrate that NF-κB is the relevant mediator of CCL20 gene transcriptional 
activation following IFI16 overexpression. The relevance of this interaction is highlighted by the 
finding that the supernatants of IFI16-overexpressing HUVEC trigger the migration of both CCR6-
positive L-DC and B cells and that this migration is significantly downregulated by the addition of 
Ab that neutralize CCL4, CCL5 and CCL20. 
Inflammation is a complex defence mechanism, which aims to contain and resolve harmful 
processes (such as infections, toxic stress and tissue damage) and protect the integrity of the human 
body. At sites of inflammation, infection or vascular injury, both local proinflammatory and 
pathogen-derived stimuli render the vessel endothelium surface attractive for incoming leukocytes 
22. This innate immune response of the endothelium consists of a well-defined and regulated multi-
step cascade involving consecutive steps of release of leukocyte-recruiting chemokines by EC and 
adhesive interactions between the leukocytes and the endothelium; thus the proinflammatory 
activation of EC is important for the tight regulation of the mechanisms underlying the 
chemoattraction of leukocytes to lesions – mechanisms that are known to involve components of the 
NF-κB complex; indeed, the NF-κB complex is considered to be the major transcription factor 
regulating the expression of EC adhesion molecules and chemokine release 23–25. Consistent with 
this, in this study we show that IFI16 triggers the expression of proinflammatory genes by 
activating the NF-κB complex. The existence of a positive interaction between IFI16 and NF-κB 
transcription factors may have far reaching implications because many genes that play a role in 
host-defense mechanisms contain NF-κB elements in their respective promoter regions. In 
conclusion, these findings reinforce the role of IFI16 as a mediator of the immunomodulatory and 
proinflammatory activities of IFN that regulate the early defence mechanisms against infections. 
 Materials and methods 
Cell lines and reagents 
HUVEC cultured in endothelial growth medium (EGM-2, Lonza, Milan) containing 2% fetal 
bovine serum, human recombinant vascular endothelial growth factor, basic fibroblast growth 
factor, human epidermal growth factor, IGF-1, hydrocortisone, ascorbic acid, heparin, gentamycin 
and amphotericin B (1 µg/mL each) were seeded into 60 mm culture dishes coated with 0.2% 
gelatin. Experiments were performed with cells between passages 2 and 6. Human embryo kidney 
293 cells (Microbix Biosystems) were cultured in minimum Eagle's medium (Invitrogen) 
supplemented with 10% fetal bovine serum (Sigma, Milan, Italy), 2 mM glutamine, 100 units of 
penicillin per milliliter and 100 µg/mL of streptomycin sulfate. 
Recombinant adenovirus preparations and HUVEC infection 
Adenovirus-derived vectors expressing either IFI16 or LacZ were generated as described previously 
9. Briefly, the pAC-CMV IFI16 containing the human IFI16 cDNA linked to a FLAG tag at the N-
terminus was cotransfected together with pJM17 into human embryonic kidney 293 cells. After 
several rounds of plaque purification, the AdVIFI16 was amplified on 293 cell monolayers and 
purified from cell lysates by banding twice on CsCl gradients. Recombinant AdVIFI16 was tested 
for IFI16 expression by Western blotting using an anti-FLAG Ab (Sigma). For cell transduction, 
preconfluent HUVEC were washed once with PBS and incubated with either AdVIFI16 or 
AdVLacZ (used as a control) at a MOI of 300 in EGM-2. After 60 min at 37°C, the virus was 
washed off and fresh medium added. Cells were cultured for 36 h before use in the experiments. 
RT-PCR analysis 
RT-PCR analysis was performed on an Mx 3000 PTM (Stratagene) using the SYBR Green I dye 
(Fermentas) as a nonspecific PCR product fluorescence label. Total cellular RNA was isolated 
using the Nucleospin Extract RNA II (Macherey Nagel). RNA (1 µg) was then retrotranscribed at 
42°C for 60 min in PCR buffer (1.5 mM MgCl2) containing 5 µM random primers, 0.5 mM dNTP 
and 100 units of RevertAid H Minus M-MuLV Reverse Transcriptase in a final volume of 20 µL. 
cDNA (1 µL), or water as control, were amplified in duplicate by RT-PCR using the Brilliant SYBR 
Green QPCR master mix (Fermentas) in a final volume of 25 µL. Primer sequences are summarized 
in Table 2. The Ct values for each gene were normalized to the Ct values for β-actin using the Ct 
equation. The level of target RNA, normalized to the endogenous reference and relative to the mock 
infected and untreated cells, was calculated by the comparative Ct method using the 2−δδCt 
equation. 
Plasmids and transfection assays 
For transfection experiments, HUVEC grown to subconfluence were detached and transfected with 
0.6 µg of the reporter vector of interest with a MicroPorator (Digital Bio) according to the 
manufacturer's instructions (1200 V, 30 ms pulse width, one impulse). Transfected cells were added 
to antibiotic-free EGM-2 in 12-well costar multiwell cell culture plates and incubated overnight at 
37°C. The medium was then replaced with complete EGM-2 medium containing 2% fetal bovine 
serum. Two hours later, cells were either infected with AdVIFI16, AdVLacZ (MOI of 300) or 
mock-infected. After 36 h, protein extracts were prepared and chemiluminescence was measured 
using the Dual Luciferase Reporter Assay System kit (Promega) at the Lumino luminometer 
(Stratec Biomedical Systems, Birkenfeld, Germany). 
Protein microarray 
Preconfluent HUVEC were washed once with PBS and incubated with either AdVIFI16 or 
AdVLacZ (used as a control) at an MOI of 300 in EGM. After 2 h at 37°C, the virus was washed off 
and fresh medium was added. After 60 h of incubation, supernatants were collected, centrifuged and 
transferred to new tubes for the chemokine/cytokine analysis according to the manufacturer's 
instructions. The RayBio human cytokine array (G Series 2000 Ab arrays; RayBiotech, Norcross, 
GA, USA) is a glass slide format. The signals from G series arrays are detected using a laser 
scanner for the detection of 174 human cytokines in single experiment. In brief, after blocking, the 
arrays were incubated with the indicated samples. Unspecific bound proteins were removed and the 
arrays were incubated with a cocktail of biotin-Ab and then fluorescent dye-conjugated streptavidin. 
Spots were visualized using detection buffer loaded to cover the entire surface and incubated for 
5 min. Image fluorescence signals were scanned and a software used that allows the fluorescence 
from all samples to be detected simultaneously or each sample to be detected on an individual basis 
as required. Spots were digitized into pixel densities. The densities were exported into spreadsheet 
software (Excel; Microsoft, Redmond, WA, USA) and the background intensity subtracted. The 
data were normalized to the positive control values provided by the manufacturer as 100% 26. 
LacZ- and IFI16-infected samples were compared for significance using Student's t-tests. p-Values 
of <0.05 were considered statistically significant. 
Detection of proteins 
CCL4, CCL5 and CCL20 chemokines were quantified in LacZ- and IFI16-infected HUVEC 
supernatants by ELISA (R&D Systems, by SPACE, Milan, Italy) in accordance with the 
manufacturer's instructions. 
Generation of monocyte-derived L-DC and purification of B cells 
Human PBMC were isolated from venous blood of voluntary healthy donors using HistoPaque 
(Sigma) density gradient centrifugation. L-DC were generated as described previously 27 starting 
from monocytes purified with a monocyte isolation kit II (Miltenyi Biotech, Bologna, Italy) by 
negative selection. After 6 days of culture, cells were >95% CD1a+ and almost CCR6+ (from 65 to 
85%) and langerin+ (from 50 to 70%) as determined by FACSCalibur (BD Bioscences, Milano, 
Italy). B cells were purified with an isolation Kit (Miltenyi Biotech) by negative selection and used 
immediately. The resulting preparations were consistently >90% CD19+CCR6+. After separation 
cells were resuspended in PBS (Sigma), supplemented with 0.2% BSA and 0.01% sodium azide, 
and incubated with fluorochrome-conjugated mAb and isotype-matched negative controls 
(DakoCytomation, Milan, Italy) after blocking nonspecific sites with rabbit IgG (Sigma) for 30 min 
at 4°C. The following PE-conjugated mAb were used: anti-CD1a, anti-CCR6 (both from R&D 
Systems), anti-langerin (BD Biosciences). FACS analysis was performed with an FACSCalibur and 
CELLQuest software (BD Biosciences). Cells were gated according to their light-scatter properties 
to exclude cell debris and contaminating lymphocytes. Migration measurements were made in 
duplicate using a transwell system (24-well plates; 5.0 µm pore sizes; Costar, Corning, NY, USA). 
A total of 600 µL of supernatant from LacZ and IFI16 infected HUVEC preincubated or not in the 
presence of anti-CCL4, anti-CCL5 and anti-CCL20 mAb for 30 min at room temperature were 
added to the lower chamber. A total of either 1.5×105 L-DC or B cells in 100 µL were added to the 
upper chamber and incubated at 37°C for 2 h. Cells that migrated into the lower chamber were 
harvested and counted by flow cytometry acquiring events for a fixed time of 30 s. The range of the 
control titration curves obtained by testing increasing concentrations of cells. The results are 
expressed as the mean number of migrated cells±SEM 28. Unpaired Student's t-tests were used to 
determine whether the differences in migration were statistically significant. 
Statistical analyses 
Statistical analyses were performed using GraphPad Prism version 5.00 for Windows (GraphPad 
Software, San Diego, CA, USA, www.graphpad.com). 
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